Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Shanahan, Kelly [1 ]
Sammons, Sarah [2 ]
Meisel, Jane L. [3 ]
Pluard, Timothy J. [4 ]
Kozlowski, Monica [5 ]
Carroll, Dominic [5 ]
Attias, Elizabeth [5 ]
机构：
[1] Metavivor Res & Support Inc, Annapolis, MD USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Emory Winship Canc Inst, Atlanta, GA USA
[4] St Lukes Canc Inst, Kansas City, MO USA
[5] Sermonix Pharmaceut, Columbus, OH USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-89
引用
下载
收藏
页码：1296 / 1296
页数：1
相关论文
共 50 条
  • [21] Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer
    Nishimura, S.
    Akiyoshi, S.
    Koga, C.
    Oikawa, M.
    Nskamura, Y.
    Ishida, M.
    Ohno, S.
    BREAST, 2015, 24 : S82 - S83
  • [22] Targeted therapies for ER+/HER2- metastatic breast cancer
    Mutsuko Yamamoto-Ibusuki
    Monica Arnedos
    Fabrice André
    BMC Medicine, 13
  • [23] SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
    Chandarlapaty, S.
    Bardia, A.
    Lord, S.
    Linden, H.
    Pelekanou, V.
    Ternes, N.
    Ming, J.
    Boutet, V.
    Boitier, E.
    Gosselin, A.
    Lee, J. Sang
    Bele, W. Dos-Santos
    Protopopov, A.
    Celanovic, M.
    Bauchet, A-L.
    Campone, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S351 - S351
  • [24] Do body composition parameters correlate with response to targeted therapy in ER+/HER2-metastatic breast cancer patients? Role of sarcopenia and obesity
    Kripa, Endi
    Rizzo, Veronica
    Galati, Francesca
    Moffa, Giuliana
    Cicciarelli, Federica
    Catalano, Carlo
    Pediconi, Federica
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [26] SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Sanders, Melinda
    Juric, Dejan
    Li, Yisheng
    Ley, Lewis Cant
    Winer, Eric P.
    Arteag, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Isakoff, Steven J.
    Kuba, Maria Gabriela
    Sanders, Melinda
    Forero-Torres, Andres
    Yap, Jeffrey T.
    Van Den Abbeele, Annick D.
    Li, Yisheng
    Arteaga, Carlos L.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.
    Finn, Richard S.
    Crown, John
    Lang, Istvan
    Kulyk, Sergey O.
    Schmidt, Marcus
    Patel, Ravi
    Thummala, Anu
    Bondarenko, Igor
    Randolph, Sophia
    Kim, Sindy
    Huang, Xin
    Donnelly, Erling
    Bartlett, Cynthia Huang
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Minimization of treatment toxicity/side effects and their impact on quality of life (QoL) in patients (pts) with ER+/HER2metastatic breast cancer (mBC)
    Sammons, Sarah
    Meisel, Jane
    Shanahan, Kelly
    Pluard, Timothy
    Chino, Fumiko
    Trapani, Dario
    Carroll, Dominic
    Kozlowski, Monica
    Attias, Elizabeth
    Kuderer, Nicole
    CANCER RESEARCH, 2024, 84 (09)
  • [30] PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN ER+/HER2-METASTATIC BREAST CANCER IN THE UK: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW
    Kurosky, S.
    Mitra, D.
    Zanotti, G.
    Kaye, J. A.
    VALUE IN HEALTH, 2015, 18 (07) : A492 - A492
12345